Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03448666
Title ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Institute of Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.